Conclusions: This initial feasibility and safety study of renal nerve denervation mediated by low and intermediate ␤-radiation dosages indicates that this approach can cause substatntial nerve damage while avoiding significant damage to the renal artery.
Background: Resistant hypertension is associated with significant cardiovascular morbidity and mortality and it poses a significant treatment challenge for physicians. The treatment of resistant hypertension by renal sympathetic denervation (RD) has demonstrated excellent short-term reductions in blood pressure (BP) at six-months as reported by the Symplicity HTN-2 Investigators. The future role of RD is evolving and long-term results will clarify it's durability. Here we assess the long-term results in the first cohort of patients to be treated with RD in Australia.
Methods:
We compared the baseline office-based BP to long-term follow-up office-based BP, number of prescribed anti-hypertensive medications, major adverse cardiac and cerebrovascular events (MACCE) and hospital admissions in 8 patients whom had undergone RD from July 2007 to January 2008. Results: Our cohort had a mean follow-up of 43 months and we found that office-based BP measurements were reduced by a mean of 30/9 mmHg when compared to baseline measurements (pϽ0.003 systolic; pϽ0.09 diastolic). The mean number of prescribed anti-hypertensive medications remained stable throughout the follow-up period (4.88 medications pre-treatment vs 4.1 medications at follow-up; pϭNS). Two patients required hospitalisation for late cerebrovascular events. There were no cardiac events reported. Conclusions: This is the longest reported follow-up of renal sympathetic denervation patients. We have demonstrated a significant and durable decrease in blood pressure. However, there has been no reduction in the number of prescribed anti-hypertensive medications. Background: Renal denervation (RDN) is a promising new treatment option for pronounced hypertension refractory to medical therapy. Interestingly, only 70-80% of patients have a relevant reduction in blood pressure (BP) three to six months after RDN when assessed by systematic 24h BP measurements. No variables have been identified to date predicting the BP response. Methods: We assessed 11 patients with bilateral renal denervation for the changes of preand postprocedural norepinephrine (NE) and epinephrine (E) levels measured directly from the renal artery (RA) and vein (RV). We defined the respective spillover for ⌬NE and ⌬E as the difference RV-RA and compared this difference before and after the procedure. Results: We assessed NE and E for 88 probes (11 patients x 2 (bilateral probes) x 2 (RA and RV) x 2(pre-and post-procedural)). There was a significant decrease of the ⌬NE RV-RA spill-over comparing pre-with post-procedural levels (184pg/mlϮ180 decrease to 97pg/mlϮ137, Pϭ0.03 for paired t-test). There was no significant change in the epinephrine levels during the procedure under conscious sedation (56pg/mlϮ192 compared to 29pg/mlϮ171, Pϭ0.62 for paired t-test). The pre-post ⌬NE RV-RA was even more pronounced when the median values were compared (P ϭ 0.02). 
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